Availability of new disease-modifying therapies (DMTs) and changes of therapeutic paradigms have led to a general improvement of multiple sclerosis (MS) prognosis in adults. It is still unclear whether this improvement also involves patients with pediatric-onset MS (POMS), whose early management is more challenging.
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis / Baroncini, D., Simone, M., Iaffaldano, P., Brescia Morra, V., Lanzillo, R., Filippi, M., Romeo, M., Patti, F., Chisari, C.G., Cocco, E., Fenu, G., Salemi, G., Ragonese, P., Inglese, M., Cellerino, M., Margari, L., Comi, G., Zaffaroni, M., Ghezzi, A.. - In: JAMA NEUROLOGY. - ISSN 2168-6157. - 78:6(2021), pp. 726-735. [10.1001/jamaneurol.2021.1008]
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis
Brescia Morra, Vincenzo;Lanzillo, Roberta;
2021
Abstract
Availability of new disease-modifying therapies (DMTs) and changes of therapeutic paradigms have led to a general improvement of multiple sclerosis (MS) prognosis in adults. It is still unclear whether this improvement also involves patients with pediatric-onset MS (POMS), whose early management is more challenging.| File | Dimensione | Formato | |
|---|---|---|---|
|
jamaneurology_baroncini_2021_oi_210019_1622672547.60916.pdf
solo utenti autorizzati
Licenza:
Accesso privato/ristretto
Dimensione
604.91 kB
Formato
Adobe PDF
|
604.91 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
